Novo Holdings A/S’s Bolt Biotherapeutics BOLT Stock Holding History

Novo Holdings A/S’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-185,200	Closed	-$5.48M	–	50
2022 Q3	$5.48M	Sell	185,200 -40,000	-18%	-$1.66M	0.26%	44
2022 Q2	$9.19M	Hold	225,200	–	–	0.45%	39
2022 Q1	$12.3M	Hold	225,200	–	–	0.65%	27
2021 Q4	$22.1M	Hold	225,200	–	–	1.05%	18
2021 Q3	$57M	Hold	225,200	–	–	2.95%	9
2021 Q2	$69.6M	Hold	225,200	–	–	3.09%	9
2021 Q1	$148M	Buy	+225,200	New	+$147M	6.12%	4

Other funds holding BOLT

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Novo Holdings A/S's BOLT Position: Q4 2022 in Review

Novo Holdings A/S sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 185,200 shares — an estimated $5.48M sold.

Novo Holdings A/S first reported a position in BOLT in Q1 2021 and held it in 7 quarters. The position peaked at $148M in Q1 2021. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

Novo Holdings A/S reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Novo Holdings A/S sold 185,200 Bolt Biotherapeutics shares in Q4 2022, an estimated $5.48M.
Novo Holdings A/S first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 7 quarters.
Novo Holdings A/S's Bolt Biotherapeutics position peaked at $148M in Q1 2021.
44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on Novo Holdings A/S's 13F filing for Q4 2022, filed 14 Feb 2023.